Two sets of guidelines—one on managing anti-rheumatic drugs perioperatively for patients undergoing total hip and knee replacements, and another that updates glucocorticoid-induced osteoporosis prevention and treatment strategies—will be featured in sessions at the 2016 ACR/ARHP Annual Meeting this month. The Sessions Sunday, Nov. 13, 2:30–3:30 p.m.: Glucocorticoid-Induced Osteoporosis Prevention and Treatment: A New ACR Clinical…
Search results for: pediatric rheumatology
State-of-the-Art Course on Interprofessional Management of Rheumatoid Arthritis
During an interactive, case-based course at the 2016 ACR/ARHP Annual Meeting, participants will develop strategies to help patients manage unique barriers to access to care and adherence…
Bipartisan RheumPAC Serves Needs of Patients and Rheumatologists
For more than a decade, the ACR’s Government Affairs Committee (GAC) has given rheumatologists a voice in the halls of Congress. Since 2007, that voice has been amplified by RheumPAC, the bipartisan political action committee for ACR/ARHP members that helps advance the policy goals of the College, rheumatology professionals and their patients. “RheumPAC allows us…
Importance of Oral Health, Mouth-Body Connection to Rheumatic Diseases Highlighted
Look inside the oral cavity of a patient for answers that go beyond what we perceive as the dentist’s domain. So goes the thinking of medical professionals interested in how oral health and bacteria-driven disease, such as periodontitis, may be linked to rheumatic disease, especially rheumatoid arthritis (RA). Bad bacteria that live in the mouth…
Plan Now to Attend the 2016 ACR/ARHP Annual Meeting
Where can you network with more than 16,000 professionals in the field of rheumatology? Where you can hear about promising research and best practices from industry leaders? How can you find out about new treatments and technologies on the horizon? You guessed it—at the 2016 ACR/ARHP Annual Meeting, to be held Nov. 11–16. As if…
Tildrakizumab Promising for Plaque Psoriasis; FDA Approves Adalimumab to Treat Panuveitis
n clinical trials, tildrakizumab was more effective than etanercept and placebo at treating moderate to severe plaque psoriasis. Adalimumab has received approval for treating non-infectious intermediate, posterior and panuveitis—its 10th FDA indication…
Rheumatologists on the Move, July 2016
HSS Holds First Rheumatology Gala The Hospital for Special Surgery (HSS) in New York City hosted a Rheumatology Gala in May. The event, held at The Park Avenue Armory in Manhattan, was held to increase awareness of HSS’s leading research and treatment of rheumatic diseases—particularly with “high-net worth people,” according to former ACR President Mary…
Conformational Flexibility in HLA-B27 Provides Clues to Development of Ankylosing Spondylitis
Understanding how human leukocyte antigen (HLA) class I molecule B27 promotes spondyloarthritis has intrigued researchers for four decades. Although the association between the single gene variant HLA-B27—specifically some of its subtypes—with ankylosing spondylitis (AS) is particularly strong, how HLA-B27 directly influences disease development has not yet been clearly explained, although hypotheses continue to be generated….
ACR Publishes National Research Agenda for 2016–2020
Defining new therapeutic targets and developing new therapies are among the goals of the 2016–2020 ACR National Research Agenda. So, too, is understanding early disease states, defining triggers of autoimmunity and examining disparities in access to medication and treatment.1 Charting a Course Every five years, the Committee on Research (COR) is tasked with helping chart the…
Arthritis Prevalence on the Rise, Creating Challenges for Healthcare System
Updated projections suggest that arthritis and arthritis-attributable activity limitation will remain large and growing problems for clinical and public health systems, which must plan and create policies and resources to address these future needs. By 2040, the number of U.S. adults with doctor-diagnosed arthritis is projected to increase 49% to 78.4 million. Can the healthcare system accommodate these projected increases? Not without changes. By 2025, the expected demand for rheumatologists is expected to exceed supply by 2,576 adult and 33 pediatric rheumatologists…
- « Previous Page
- 1
- …
- 78
- 79
- 80
- 81
- 82
- …
- 96
- Next Page »